





THE NASDAQ STOCK MARKET
LISTING QUALIFICATIONS DEPARTMENT
1100 PENNSYLVANIA AVE. N.W.
WASHINGTON, D.C. 20004

Gary Sundick
Vice President
Listing Qualifications



07073949



By Facsimile and First Class Mail

October 10, 2007

Ms. Cecile Peters
Chief, IT Services
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549

PROCESSED

OCT 15 2007

J THOMSON
FINANCIAL

001-33730

CERTNAS

Dear Ms. Peters:

This is to certify that on October 9, 2007 The Nasdaq Stock Market (the "Exchange") received from Targanta Therapeutics Corporation (the "Registrant") a copy of the Registrant's application on Form 8-A 12(b) for the registration of the following security:

Common Stock, \$0.0001 par value

We further certify that the security described above has been approved by the Exchange for listing and registration upon official notice of issuance.

We understand that the Registrant is seeking effectiveness of the Form 8-A 12(b) concurrently with effectiveness of its 1933 Act Registration Statement, and we hereby join in such request.

Sincerely,

Gary Sundick

END